RedHill Biopharma (RDHL) Registration Filing summary

Company overview and business model

• Specialty biopharmaceutical company focused on GI, infectious diseases, medical countermeasures, and oncology, aiming to become a leading specialty biopharma firm.

• Commercializes Talicia® in the U.S. through a joint venture with Cumberland and explores additional global partnerships.

• Pipeline includes five clinical-stage therapeutic candidates, with a strategy of in-licensing or acquiring products with high therapeutic and commercial potential.

Financial performance and metrics

• As of June 30, 2025, reported a stockholders' deficit of $4.68 million, but regained Nasdaq compliance by December 2025.

• Pro forma as adjusted capitalization (post-offering) shows $13.5 million in cash and $36.3 million in total shareholders' equity.

• Recent financings include $3.3 million from the Any Market Purchase Agreement and $3.3 million from the Wainwright ATM program.

Use of proceeds and capital allocation

• No proceeds from the resale of ADSs by the selling shareholder; proceeds from Pre-Funded Warrant exercises will be used for general corporate purposes.

• Any future earnings are intended to be reinvested in business development and expansion; no plans to pay dividends.